Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Monday reported positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial evaluating Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) in previously untreated patients with PD-L1 positive metastatic triple-negative breast cancer.
Keytruda is owned by US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada.
The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to the current standard of care, Keytruda plus chemotherapy.
This marks the first pivotal Phase 3 trial to show superiority of a Trop-2-directed antibody-drug conjugate combined with immunotherapy in this setting.
An early trend toward overall survival improvement was also observed, although the data remain immature.
The safety profile of the Trodelvy-Keytruda combination was consistent with known profiles of each therapy, and no new safety signals emerged.
Trodelvy is the only approved Trop-2-directed antibody-drug conjugate with demonstrated survival benefits in multiple metastatic breast cancer indications.
The ASCENT-04 results support the potential of Trodelvy plus Keytruda as a new first-line treatment option for patients with PD-L1 positive locally advanced or metastatic triple-negative breast cancer.
Cinclus Pharma signs EUR220m European commercialisation deal with Zentiva for acid reflux therapy
Sanofi to acquire Vigil Neuroscience for USD470m to expand Alzheimer's pipeline
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
Revalesio reports further analysis from Phase 2 RNS60 trial for acute ischemic stroke treatment
AnnJi reports positive Phase 1/2a results in Spinal and Bulbar Muscular Atrophy trial
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
MSD expands clinical development of Orion's opevesostat to include women's cancers
Promontory Therapeutics reports successful FDA meeting after Phase 2 study of PT-112
Trevi Therapeutics reports additional results from Phase 2a RIVER trial of Haduvio
Accropeutics reports positive data from Phase 2 psoriasis treatment trial
NextCell Pharma partners with Fujifilm Irvine Scientific to deliver integrated MSC solutions
Lifecare files for first human trial of glucose monitoring implant, targeting CE-mark
EXACT Therapeutics reports strong Phase 1 results for ACTIVATE trial in colorectal liver metastases